Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.
about
Intrabodies as neuroprotective therapeuticsVisualizing posttranslational and epigenetic modifications of endogenous proteins in vivoSelection for intrabody solubility in mammalian cells using GFP fusionsBifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Chaperoning roles of macromolecules interacting with proteins in vivo.Generation of an intrabody-based reagent suitable for imaging endogenous proliferating cell nuclear antigen in living cancer cells.Functional inhibition of β-catenin-mediated Wnt signaling by intracellular VHH antibodiesEnhanced production of a single domain antibody with an engineered stabilizing extra disulfide bondEngineered Autonomous Human Variable DomainsBifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1.Genetically encoded system to track histone modification in vivo.Lysine and arginine content of proteins: computational analysis suggests a new tool for solubility design.Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteinsFusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.Modifications of a signal sequence for antibody secretion from insect cells.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.Soluble expression of proteins correlates with a lack of positively-charged surface.Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold.Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals.Molecular Modeling for Protein Aggregation and FormulationTargeted Intracellular Delivery of Antibodies: The State of the Art
P2860
Q27003896-B551948C-C345-40EB-AA66-027C99736649Q28083442-CEE91221-2D5B-4B11-AD38-3C7F3E682F43Q31035688-620CC7AB-8F1F-4302-93D1-DD41F1092E0FQ34117333-D50F8EFC-B6BE-4403-A416-0E2AD054D1C7Q35036093-C0C283DF-CDAA-40D9-A586-D2C8E63D9222Q35209715-C5A7542B-D68A-4029-B205-AA3E919FC592Q35530296-C180E334-B8E7-4A2E-ADB4-7FF8EBBE4436Q35800979-2F854280-B637-4472-B555-499F774EFCF1Q36140177-EDCB44E6-7A89-46E1-987C-7A82DF0F7230Q36185625-15AFD7C6-FF62-483C-A67B-9B478A2E55AFQ37052361-1BDBFD79-B07C-44D1-B739-28033CE782E4Q37094330-61C76510-EEED-4333-8B2D-CBA39BE8BE69Q37451005-8D43416B-9BEA-4E00-9F5D-CF7797616FE2Q37961564-93847DC7-4531-482E-8F87-749CF11C7980Q39289367-BDACCFF7-397C-425C-B5EB-01708EF85414Q41986713-4A14A2D5-F1E3-4FF9-BEEF-723764549BB7Q42854245-C27E1967-7852-4F52-8549-1F435FE7C69BQ45147882-7BF44CF8-1705-4E95-997D-D7554BD53193Q53642992-B31261BA-CA3E-4082-9C8B-F580B93BD7DFQ54943679-E5C65DEB-8CA4-4EC3-8356-BCC1C945EF95Q57341107-C4EF61F4-BF94-4FCE-B33F-CC4BEDB7CA83Q58566968-0F211046-F348-4CF9-AAAB-062661CFC649
P2860
Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@ast
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@en
type
label
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@ast
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@en
prefLabel
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@ast
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@en
P2093
P2860
P356
P1476
Physico-chemical determinants ...... n in mammalian cell cytoplasm.
@en
P2093
Anne Messer
Charles B Shoemaker
Michael R Sierks
P2860
P304
P356
10.1093/PROTEIN/GZQ022
P577
2010-04-08T00:00:00Z